News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Rx3 Pharmaceuticals, Inc. Expands Board Of Directors

9/27/2006 10:58:51 AM

SAN DIEGO, Sept. 27 /PRNewswire/ -- Rx3 Pharmaceuticals, Inc., an anti-infective drug discovery company, announced today that it has recently expanded its Board of Directors to complement the Company's experienced management team, scientists, and clinical advisors. Joining the Board are Julia Brown, David Kabakoff, Ph.D., and Takashi Kiyoizumi, M.D., Ph.D. They will work closely with the Company's existing Board members, John Finn, Ph.D. and Jeffrey Stein, Ph.D.

"We are excited to have these experienced biotech executives join in our efforts to build next generation antibiotics for life threatening infections," said John Finn, President of Rx3 Pharmaceuticals. "They bring a wealth of relevant business and science experience that will be invaluable for Rx3's next stage of development."

Ms. Brown is a seasoned life sciences executive, having worked in various senior capacities at Amylin, Dura, and Eli Lilly. She has spent a substantial portion of her career involved in the development and commercialization of various antibiotics. Dr. Kabakoff served previously as CEO of Salmedix and Corvas. He has extensive experience in founding and building biotech companies into successful companies. Dr. Kiyoizumi previously served as founder and CEO of MediciNova and CEO of Tanabe Research Laboratories USA. His scientific and business expertise in biotech commercialization activities and in particular business development related to parties in Asia is substantial. All three individuals have made an investment in the Company as part of joining its Board of Directors.

About Rx3 Pharmaceuticals

Rx3 Pharmaceuticals is a drug discovery company applying its structure-based drug design technologies to its antimicrobial programs. These programs target novel proteins in validated biological pathways. For more information, visit

Rx3 Pharmaceuticals, Inc.

CONTACT: John P. Schmid, Chief Financial Officer of Rx3 Pharmaceuticals,Inc., +1-858-452-0370, ext. 105,; or Media, KarenKristofferson of Mentus, Life Science, +1-858-455-5500, ext. 275,, for Rx3 Pharmaceuticals, Inc.

Read at

comments powered by Disqus